Postdoc Position Available

Craig Mullen mullen at utmdacc.mda.uth.tmc.edu
Mon Feb 17 17:24:04 EST 1997


Postdoctoral Position Available in Cancer Immunology
Univ. of Texas M.D. Anderson Cancer Center
Houston, Texas

Feb. 17, 1997

A funded position for a postdoctoral investigator is
available immediately.  The focus of the lab's work is the
induction of antigen specific cytolytic T cells for the
treatment of minimal residual metastatic cancer.  Two
projects are underway.  The first involves the
quantification of CTL responses to tumor associated antigens
induced in vivo by chemoablation of poorly immunogenic
tumors genetically engineered to express metabolic suicide
genes.  The additional contribution of cytokine expression
in the tumor microenvironment is also studied.  The second
project studies graft versus tumor effects in allogeneic
bone marrow transplantation.  Specifically the impact of
active immunization of donors with genetically engineered
recipient tumor cells on generation of antitumor T cells
will be assessed, as well as the changes in graft versus
host disease activity.

Candidates for this position should have some background in
immunology, hematology and molecular biology.  Techniques
used in the lab include: development and use of retroviral
vectors, subcloning of plasmids, tissue culture, cellular T
cell assays, tumor transplantation, and bone marrow
transplantation.  In vivo experiments in inbred mice play an
important role in the projects.

This position is immediately available.  Salary will depend
on qualifications.  Please send curriculum vitae and the
names and telephone numbers of three references to:

Craig A. Mullen, M.D., Ph.D.
Depts. of Experimental Pediatrics & Immunology
U.T. M.D. Anderson Cancer Center
Room B7.4518, Box 88
1515 Holcombe Blvd.
Tel: 713-792-3314
Fax: 713-794-4373
email: mullen at utmdacc.mda.uth.tmc.edu


Representative publications:

Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing
the cytosine deaminase suicide gene can be eliminated
in vivo with 5-fluorocytosine and induce protective
immunity to wild type tumor. Cancer Res, 54:1503-1506,
1994.
 
Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A,
Cavallo F, Giovarelli M, Forni G. 5-fluorocytosine
induced eradication of murine adenocarcinomas
engineered to express the cytosine deaminase suicide
gene requires host immune competence and leaves an
efficient memory. J. Immunol., 154:5302-5312, 1995.

Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic
pulmonary metastases with recombinant autologous tumor
vaccine expressing IL-6 and E. coli cytosine deaminase
suicide genes. Cancer Research, 56:1361-1366, 1996.

-- 
Dr. Craig Mullen
mullen at utmdacc.mda.uth.tmc.edu



More information about the Immuno mailing list